Several blood-based prognostic biomarkers have shown potential for risk stratification in EC, including proteins such as cancer antigen 125 (CA125) and Human Epididymis Protein 4 (HE4), as well as circulating cell-free tumour DNA levels [17, 18]. The gene discussed is MUC16; the disease is neoplasm.